Clinical Research Of Yifei Prescription Combined With Bevacizumab Plus AP Regimen In The Treatment Of Advanced Lung Adenocarcinoma

Obiective:In this study,To explore the advantages of Yifei prescription in the treatment of advanced lung adenocarcinoma.by observing the changes in short-term curative effect,TCM syndrome scores,Kamofsky score and quality of life score of patients,tumor markers,safety,etc.in patients with advanced lung adenocarcinoma treated by Yifei prescription combined with bevacizumab plus AP regimen.Method:According to the diagnostic criteria of traditional Chinese medicine and modern medicine and the inclusion,exclusion criteria,60 patients with stage ⅢB ⅢC and Ⅳ lung adenocarcinoma were selected.The patients were randomly assigned to The experimental group(Yifei prescription combined with bevacizumab plus AP regimen group,30 cases)and the control group(bevacizumab plus AP regimen group,30 cases)record the lesion size,TCM symptom score,quality of life score and tumor markers,blood routine,liver and kidney function,hemorrhage,proteinuria and other safety indexes before and after treatment.And the date were analyzed statistically with the help of SPASS 19.0 statistical software.Results:1.Comparison of recent objective effects,the ORR of the experimental group was 26.67%and 86.67%,which was better than that of the control group.The ORR was 23.33%and 83.33%.There was no significant difference between the two groups(P>0.05).2.Comparison of syndromes integral of TCM,after treatment,In the experimental group,2 cases were excellence,16 cases were effective,12 cases were ineffective,the total effective rate was 56.67%.In the control group,1 cases were excellence,7 cases were effective,and 22 cases were ineffective.The total effective rate was 22.33%.The difference between the two groups was statistically significant(P<0.05).3.Comparison of Physical condition,the KPS score of the experimental group was significantly higher than that of the control group(P<0.05).The experimental group was superior to the control group in physical improvement.4.Comparison the quality of life score,In the field of function,The cognitive function of the experimental group improved after treatment(P<0.05),and the physical function improved significantly(P<0.01).The body function of the control group was significantly better than before(P<0.01).In the area of symptoms,nausea,vomiting and pain were improved in the experimental group after treatment(P<0.05),fatigue,loss of appetite,and constipation were significantly improved compared with before treatment(P<0.01).The fatigue,loss of appetite,constipation and total health of the experimental group were superior to those of the control group after treatment.The difference was statistically significant(P<0.05).5.Comparison of tumor markers,After treatment,the levels of CEA CA125 CY21-1 in the trial group were lower than those before treatment(P<0.05).The level of CEA CY21-1 in control group was lower than that before treatment(P<0.05).The CY21-1 comparison between the two groups after treatment,the experimental group decreased more than the control group(P<0.05).6.Comparison of safety.There was no significant difference in the incidence of side effects between the two groups(P>0.05).Conclusion:The therapeutic mode of Yifei prescription combined with bevacizumab plus AP regimen,compared with the bevacizumab plus AP regimen,It is effective in relieving clinical symptoms,improving physical condition scores,improving quality of life,and reducing tumor marker levels.There were no obvious adverse reactions and the safety was good.